Video

When a suboptimal clinical response is encountered with TNF or interleukins antagonists, what other strategies may be effective? How might an IL-6 inhibitor fit into the treatment plan?

Name: When a suboptimal clinical response is encountered with TNF or interleukins antagonists, what other strategies may be effective? How might an IL-6 inhibitor fit into the treatment plan?
Uploaded: 2017-02-27T00:00:00+00:00
Description: When a suboptimal clinical response has been encountered with TNF or interleukins antagonists, what other biologic strategies have been shown to be effective in clinical trials? How are these sequencing decisions made and where might an IL-6 inhibitor — with a different MoA — fit into the treatment plan?

Published: February 27, 2017

When a suboptimal clinical response is encountered with TNF or interleukins antagonists, what other strategies may be effective? How might an IL-6 inhibitor fit into the treatment plan?

When a suboptimal clinical response has been encountered with TNF or interleukins antagonists, what other biologic strategies have been shown to be effective in clinical trials? How are these sequencing decisions made and where might an IL-6 inhibitor — with a different MoA — fit into the treatment plan?

Overview

CLICK HERE FOR CME CREDIT

Created by

Presenter

Yvonne Sherrer, MD

Medical Director/Director of Clinical Research
Centre for Rheumatology, Immunology and Arthritis
Fort Lauderdale, FL

Related Videos

Video

What do you think are some of the most important unmet needs in RA?

Video

What are the strengths and weaknesses of conventional measures of RA disease activity (i.e., ACR scores) as compared to the increasingly important patient-reported outcomes (PROS)?

What are the strengths and weaknesses of conventional measures of RA disease activity (i.e., ACR scores) as compared to the increasingly important patient-reported outcomes (PROS) that are being used in clinical trials?

Video

What do studies and guidelines suggest as successful therapeutic strategies for RA patients who have been inadequate responders to TNF therapy?

What do studies and guidelines suggest as successful therapeutic strategies for RA patients who have been inadequate responders to TNF therapy? On the basis of what criteria is the decision made to switch to an Il-6 inhibitor or an agent ...